Anti-CUEDC2 Antibody Picoband® Fluoro488 Conjugated

CUEDC2 (Cue Domain-Containing Protein 2) is involved in ubiquitin-and proteasome-mediated degradation of progesterone receptor (PR, or PGR) and estrogen receptor (ER) -alpha. Hartz (2011) mapped the CUEDC2 gene to chromosome 10q24.32 based on an alignment of the CUEDC2 sequence with the genomic sequence (GRCh37) . Using coimmunoprecipitation analysis and protein pull-down assays, Zhang et al. (2007) confirmed that CUEDC2 interacted with the PRB isoform of PR. Mutation analysis revealed that the IF domain of PRB and the CUE domain of CUEDC2 were required for the interaction. CUEDC2 reduced PRB protein content and promoted progesterone-induced PRB degradation via the ubiquitin-proteasome pathway.

A synthetic peptide corresponding to a sequence at the C-terminus of human CUEDC2, identical to the related mouse sequence, and different from the related rat sequence by one amino acid.

Significantly up-regulated in breast tumor tissues compared with matched adjacent normal tissues (at protein level) . Levels inversely correlate with ESR1 in breast cancers and are lower in low-grade tumors compared to high-grade tumors.

Down-regulates ESR1 protein levels through the ubiquitination-proteasome pathway, regardless of the presence of 17 beta-estradiol. Also involved in 17 beta-estradiol-induced ESR1 degradation. Controls PGR protein levels through a similar mechanism. .

1. Hartz, P. A. Personal Communication. Baltimore, Md. 7/26/2011. 2. Pan, X., Zhou, T., Tai, Y.-H., Wang, C., Zhao, J., Cao, Y., Chen, Y., Zhang, P.-J., Yu, M., Zhen, C., Mu, R., Bai, Z.-F., and 10 others. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nature Med. 17: 708-714, 2011. 3. Zhang, P.-J., Zhao, J., Li, H.-Y., Man, J.-H., He, K., Zhou, T., Pan, X., Li, A.-L., Gong, W.-L., Jin, B.-F., Xia, Q., Yu, M., Shen, B.-F., Zhang, X.-M. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J. 26: 1831-1842, 2007.